Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for tough leukemia: MK-1045 takes on standard therapy

NCT ID NCT07570173

Recruiting now Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 8 times

Summary

This study compares a new immunotherapy, MK-1045, to the standard drug blinatumomab in people whose B-cell acute lymphoblastic leukemia has returned or stopped responding to treatment. About 340 adults with CD19-positive leukemia will receive one of the two treatments. The goal is to see if MK-1045 leads to more complete remissions and longer survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia Burkitt lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Aarhus Universitetshospital. Hæmatologisk afdeling ( Site 0804)

    RECRUITING

    Aarhus Nord, Central Jutland, 8200, Denmark

  • Amsterdam UMC ( Site 2001)

    RECRUITING

    Amsterdam, North Holland, 1081 HV, Netherlands

  • Evangelismos General Hospital of Athens ( Site 5100)

    RECRUITING

    Athens, Attica, 106 76, Greece

  • General Hospital of Athens "Laiko" ( Site 5101)

    RECRUITING

    Athens, Attica, 115 27, Greece

  • HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 3009)

    RECRUITING

    Madrid, 28233, Spain

  • Haddasah Medical Center ( Site 0900)

    RECRUITING

    Jerusalem, 9112001, Israel

  • Hospital Universitario de Salamanca ( Site 3002)

    RECRUITING

    Salamanca, 37007, Spain

  • Institut Català d'Oncologia (ICO) - Badalona ( Site 3001)

    RECRUITING

    Badalona, Barcelona, 08916, Spain

  • Odense Universitetshospital ( Site 0801)

    RECRUITING

    Odense, Region Syddanmark, 5000, Denmark

  • Policlinico Universitario Agostino Gemelli ( Site 1003)

    RECRUITING

    Rome, Roma, 00168, Italy

  • Radboud UMC ( Site 2003)

    RECRUITING

    Geert Grooteplein-Zuid 8, Gelderland, 6500 HB, Netherlands

  • Rambam Health Care Campus ( Site 0903)

    RECRUITING

    Haifa, 3109601, Israel

  • Rigshospitalet ( Site 0802)

    RECRUITING

    Copenhagen, Capital Region, 2100, Denmark

  • Sheba Medical Center ( Site 0902)

    RECRUITING

    Ramat Gan, 5265601, Israel

  • Sourasky Medical Center. ( Site 0904)

    RECRUITING

    Tel Aviv, 6423906, Israel

  • Tokyo Metropolitan Komagome Hospital ( Site 2106)

    RECRUITING

    Bunkyo, Tokyo, 113-8677, Japan

  • Toranomon Hospital ( Site 2101)

    RECRUITING

    Minato, Tokyo, 105-8470, Japan

  • University Hospital of Ioannina ( Site 5103)

    RECRUITING

    Ioannina, 455 00, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.